Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: A prospective, randomized, open-label, placebo-controlled pilot study - Arrieta, Antonio C.; Shea, Kathy; Dhar, Vijay; Cleary, John P.; Kukreja, Sudeep; Morris, Mindy; Vargas-Shiraishi, Ofelia M.; Ashouri, Negar; Singh, Jasjit (Clinical therapeutics, 2010)
Keywords: Amphotericin B - administration & dosage; Amphotericin B - adverse effects; Antifungal agents; Antifungal Agents - administration & dosage; Antifungal Agents - adverse effects; Biological and medical sciences; Birth weight; Bone marrow; Candida prophylaxis; Candidiasis - diagnosis; Candidiasis - etiology; Candidiasis - prevention & control; Children & youth; Disease prevention; Diseases of mother, fetus and pregnancy; Drug Administration Schedule; Female; Fungal infections; Gestational Age; Gynecology. Andrology. Obstetrics; Humans; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Infectious diseases; Intensive care; Internal Medicine; liposomal amphotericin B; Male; Medical Education; Medical sciences; Mortality; neonates; Pediatrics; Pharmacokinetics; Pharmacology. Drug treatments; Pilot Projects; Pregnancy. Fetus. Placenta; Premature babies; Premature birth; Prospective Studies; Stem cell transplantation; Treatment Outcome; United States--US; California; liposomal amphotericin B; Candida prophylaxis; neonates; Premature; Candidiasis; Mycosis; Pregnancy disorders; Infant; Fungi; Very low birthweight; Prospective; Prevention; Antiprotozoal agent; Antifungal agent; Randomization; Weekly; Fungi Imperfecti; Human; Liposome; Infection; Newborn diseases; Antibiotic; Newborn; Prematurity; Amphotericin B; Polyenic compound; Candida; Placebo; Parasiticide